Cornerstone_Pharma_Logo_V (1).png
Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE
June 16, 2022 14:14 ET | Cornerstone Pharmaceuticals, Inc.
Cranbury, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael...
Rafael logo.png
Rafael Pharmaceuticals Announces Successful Completion of Dose Escalation with No Dose-Limiting Toxicity (DLT) in First Cohort of APOLLO 613 Phase 1/2 Clinical Trial of CPI-613® (Devimistat) in Patients with Relapsed Clear Cell Sarcoma
January 06, 2022 08:30 ET | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a company focused on the growing field of cancer metabolism-based therapeutics, announced...
Rafael logo.png
Rafael Pharmaceuticals Announces APOLLO613 Phase I/II Clinical Trial of CPI-613® (devimistat) in Combination with Hydroxychloroquine in Patients with Relapsed Clear Cell Sarcoma Begins Enrollment at City of Hope in Duarte, Calif.
September 27, 2021 08:00 ET | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced that the...
Rafael logo.png
President and CEO of Rafael Pharmaceuticals, Sanjeev Luther, to Present at the 11th Annual World Orphan Drug Congress USA 2021
August 26, 2021 08:00 ET | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced that...
Rafael logo.png
Rafael Pharmaceuticals Announces the Successful Completion of Phase 1b Clinical Trial and Initiates Phase 2 for CPI-613® (devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer
August 25, 2021 10:00 ET | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Aug. 25, 2021 (GLOBE NEWSWIRE) -- -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced...
Rafael logo.png
Rafael Pharmaceuticals Announces Positive Preplanned Interim Futility Analysis of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)
July 01, 2021 08:00 ET | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., July 01, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced positive...
Rafael logo.png
Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613® (Devimistat) at the American Society of Clinical Oncology (ASCO) 2021 Virtual Scientific Program
May 26, 2021 09:00 ET | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced...
Screen Shot 2021-01-12 at 7.57.32 PM.png
Rafael Pharmaceuticals Crosses Enrollment of 150 Patients in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)
March 30, 2021 09:00 ET | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., March 30, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced...
Screen Shot 2021-01-12 at 7.57.32 PM.png
Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference
January 19, 2021 11:30 ET | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced...
Screen Shot 2021-01-12 at 7.57.32 PM.png
Rafael Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference
January 13, 2021 09:00 ET | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced...